-
Product Insights
NewGTPase KRas – Drugs In Development, 2024
The GTPase KRas pipeline drugs market research report outlays comprehensive information on the GTPase KRas targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Undisclosed, Infectious Disease, and Immunology which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Unspecified, Epstein–Barr Virus (HHV-4) Infections, and Unspecified Immunological Disorders. It also reviews key players involved in GTPase KRas...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sotorasib in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sotorasib in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sotorasib in Colorectal Cancer Drug Details: Sotorasib (Lumakras / Lumykras) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sotorasib in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sotorasib in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sotorasib in Metastatic Colorectal Cancer Drug Details: Sotorasib (Lumakras /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-4396 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-4396 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-4396 in Solid Tumor Drug Details: ASP-4396 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-3706674 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-3706674 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-3706674 in Gastric Cancer Drug Details: BI-3706674 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-3706674 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-3706674 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-3706674 in Esophageal Cancer Drug Details: BI-3706674 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-3706674 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-3706674 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-3706674 in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCB-161734 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCB-161734 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INCB-161734 in Colorectal Cancer Drug Details: INCB-161734 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCB-161734 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCB-161734 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INCB-161734 in Solid Tumor Drug Details: INCB-161734 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCB-161734 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCB-161734 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INCB-161734 in Pancreatic Ductal Adenocarcinoma Drug Details: INCB-161734 is under...